Enhanced Near-Infrared Imaging for Prostate Cancer Diagnosis and Treatment

This inventive concept presents a suite of advancements in near-infrared imaging for prostate cancer diagnosis and treatment, offering improved sensitivity, specificity, and efficacy in minimally invasive medical procedures.

The original patent, 'Compositions of near IR closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands,' demonstrated the potential of near-infrared imaging for prostate cancer diagnosis. However, limitations in the original composition's fluorescence, detection, and targeting capabilities hindered its widespread adoption. This new inventive concept addresses these limitations by introducing novel formulations, detection systems, and methods for visualizing and treating prostate cancer.

The new inventive concept comprises four key aspects: (1) a method for visualizing tissue under near-infrared radiation, utilizing a composition with enhanced fluorescence; (2) a system for detecting prostate specific membrane antigen in patients, incorporating a near-infrared radiation source, detector, and processing unit; (3) a composition featuring a near IR, closed chain, sulfo-cyanine dye, prostate specific membrane antigen ligand, and a metal ion for enhanced fluorescence; and (4) a method for determining the efficacy of prostate specific membrane antigen-targeted therapies by measuring fluorescence. These advancements enable more accurate and efficient diagnosis, treatment, and monitoring of prostate cancer.

The new inventive concept introduces several non-obvious improvements over the original patent, including the use of metal ions to enhance fluorescence, the development of a system for detecting prostate specific membrane antigen, and the creation of a method for determining therapy efficacy. These innovations provide a significant advancement in the field of near-infrared imaging for prostate cancer diagnosis and treatment.

Alternative embodiments of the inventive concept could include varying the type and concentration of metal ions, utilizing different near-infrared radiation sources, or incorporating additional biomarkers for enhanced specificity. Variations of the system and method could be developed for use in different medical procedures or for targeting other types of cancer.

The enhanced near-infrared imaging system and methods have significant commercial potential in the medical device and pharmaceutical industries, particularly in the context of prostate cancer diagnosis and treatment. The target market includes hospitals, clinics, and research institutions, with potential for expansion into other medical specialties and applications.